These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30124087)

  • 1. Neovascularization: an attractive but tricky target in thyroid cancer.
    Tasoulas J; Tsourouflis G; Theocharis S
    Expert Opin Ther Targets; 2018 Sep; 22(9):799-810. PubMed ID: 30124087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF as a potential target in lung cancer.
    Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
    Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
    Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
    Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis in salivary gland tumors: from clinical significance to treatment.
    Theocharis S; Gribilas G; Giaginis C; Patsouris E; Klijanienko J
    Expert Opin Ther Targets; 2015 Jun; 19(6):807-19. PubMed ID: 25956454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VEGF pathway in lung cancer.
    Alevizakos M; Kaltsas S; Syrigos KN
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1169-81. PubMed ID: 24085262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
    Brilli L; Pacini F
    Future Oncol; 2011 May; 7(5):657-68. PubMed ID: 21568681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis in biliary tract cancer: targeting and therapeutic potential.
    Rimini M; Casadei-Gardini A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):411-418. PubMed ID: 33491502
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-angiogenic therapies for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
    Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
    Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis.
    Cao Z; Shang B; Zhang G; Miele L; Sarkar FH; Wang Z; Zhou Q
    Biochim Biophys Acta; 2013 Dec; 1836(2):273-86. PubMed ID: 23933263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles and role-players in thyroid cancer angiogenesis.
    Rajabi S; Dehghan MH; Dastmalchi R; Jalali Mashayekhi F; Salami S; Hedayati M
    Endocr J; 2019 Apr; 66(4):277-293. PubMed ID: 30842365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
    Schoenberger J; Grimm D; Kossmehl P; Infanger M; Kurth E; Eilles C
    Endocrinology; 2004 Mar; 145(3):1031-8. PubMed ID: 14607854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoglin for tumor imaging and targeted cancer therapy.
    Paauwe M; ten Dijke P; Hawinkels LJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis-related molecular targets in esophageal cancer.
    Hong L; Li S; Han Y; Du J; Zhang H; Li J; Zhao Q; Wu K; Fan D
    Expert Opin Investig Drugs; 2011 May; 20(5):637-44. PubMed ID: 21443389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
    Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.
    Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F
    Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.